Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) ...

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...

PD-1 Inhibitor Drug PD-1 Inhibitor Drugs Market poised for robust growth, driven by rising cancer therapies and expanding immuno-oncology a ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...